Status: Recruiting
CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery
Randomized, double-blind, clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg/day in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery. Subjects will be allocated in 2 groups. One group will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days. A second group will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days
Participants needed: 80
Trial details
Phase: Phase 2Age: 40-75Biological sex: AllType: InterventionalSponsor: Clarent Biopharma, Inc.Updated: Jul 7, 2026Locations: 1
Eligibility criteria
Men or women [+8]
History of respiratory depression, severe bronchial asthma, chronic obstructive... [+18]